Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Crucell to raise EUR 80 million, acquire SBL

Crucell (Euronext:CRXL; CRXL) said it plans to raise EUR 80 million ($102.6 million) through the

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE